<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498654</url>
  </required_header>
  <id_info>
    <org_study_id>Ty800-07-0001</org_study_id>
    <nct_id>NCT00498654</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of a Single Oral Dose Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avant Immunotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avant Immunotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to examine the safety and immunogenicity of Ty800 oral vaccine
      in healthy adult subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Baseline through Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactogenicity</measure>
    <time_frame>Baseline through Month 1 follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longterm safety and immunogenicity</measure>
    <time_frame>Month 1 to 6 post-dosing</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Typhoid Fever</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ty800 (Salmonella typhi) Oral Vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Males or Females aged 18 to 55 years, inclusive

          -  Capable of understanding and complying with the protocol requirements and be available
             for the duration of the protocol

        Exclusion Criteria:

          -  History of malignancy, immunocompromised conditions or currently receiving
             immunosuppressive treatment including systemic steroids

          -  History of Typhoid Fever infection, vaccination against typhoid fever or participation
             in a Clinical Trial using S.typhi organism at any time

          -  History of travel to a typhoid endemic region within the last 5 years or history of
             raising a child from an endemic area. Endemic regions are South and East Asia, the
             Indian Subcontinent, Africa and Central and South America including Mexico

          -  History of persistent diarrhea, blood in stool, peptic ulcer disease, or inflammatory
             bowel disease

          -  Allergies or sensitivities to antibiotics, notably quinolones, penicillins,
             sulfonamides, cefalosporins and chloramphenicol, and components of the buffer
             solution, notably aspartame.

          -  People who are commercial food handlers, day care workers, or health care workers
             involved in direct patient care. Also people with young children under 2 years of age
             at home or household contacts who are immunocompromised, pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clark McKeever, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accelovance LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelovance LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance LLC</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance LLC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance LLC</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <last_update_submitted>June 27, 2008</last_update_submitted>
  <last_update_submitted_qc>June 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2008</last_update_posted>
  <responsible_party>
    <organization>AVANT Immnunotherapeutics</organization>
  </responsible_party>
  <keyword>Prevention of Typhoid Fever in Adult Travelers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Typhoid Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

